Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Quest Diagnostics Inc (DGX) vs Lithium Americas Corp (LAC) Price & Performance

Quest Diagnostics IncTrade
Lithium Americas CorpTrade

Price performance (Past 24H)

Key statistics

Quest Diagnostics Inc vs Lithium Americas Corp — how do they compare? Quest Diagnostics Inc trades at $237.5 (market cap $26.21B), while Lithium Americas Corp trades at $3.25 (market cap $1.18B). The key difference: Quest Diagnostics Inc is far larger — about 22.2× Lithium Americas Corp's market cap, and Quest Diagnostics Inc pays a 1.45% dividend while Lithium Americas Corp pays none. Which is the better fit depends on your goals.

DGXLAC
Market Cap
$26.21B$1.18B
Sector
HealthBasic Materials
52-Week High
$238.50$10.05
52-Week Low
$173.49$2.71
Enterprise Value
$31.97B$1.29B
Dividend Yield
1.45%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Quest Diagnostics Inc

Quest Diagnostics (DGX) trades at $237.63, down slightly by 0.3% today, but maintains strong momentum with three consecutive quarterly earnings beats and a raised 2026 outlook. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid revenue growth to $11.04 billion in 2025 and improving profit margins. Recent news highlights surging testing demand and AI implementation driving operational efficiency.

DGX presents a favorable investment case with analyst consensus price target of $249.50 offering 5% upside potential. Strong testing demand, strategic partnerships, and earnings momentum support growth, though elevated debt levels and margin pressures from lower-margin deals pose moderate risks. The stock's current valuation at 25.21 P/E appears reasonable given growth prospects.

Lithium Americas Corp

Lithium Americas Corp. (LAC) trades at $3.30, up 1.54% today, with a bullish technical signal from moving averages but negative profitability metrics including an ROE of -11.35% and net loss of $122.09 million in 2025. Recent news highlights a $175 million financing to strengthen the balance sheet as Thacker Pass approaches peak construction, though earnings have been volatile with mixed quarterly beats and misses.

The outlook is balanced: analyst consensus shows 47% buy ratings with no sells, reflecting optimism on lithium demand, but high execution risk remains given negative cash flow from operations and substantial capital needs. Upside depends on successful project development, while downside risks include funding pressures and commodity price volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Quest Diagnostics Inc

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.

Read more on DGX

About Lithium Americas Corp

Lithium Americas is a resource company focused on developing the Thacker Pass project in Nevada, the largest known lithium resource in the US. It aims to become a major supplier for the electric vehicle battery market.

Read more on LAC